[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351319-105":59,"doc-detail-351319-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","crispr-cas9-screening-identifies-atox1-driven-cisplatin-resistance-mechanisms-in-liver-cancer-and-evaluates-targeted-inhibitor-efficacy","CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacy","","Liver cancer treatment with cisplatin is frequently limited by intrinsic and acquired drug resistance, keeping 5-year survival below 20%. Genome-wide CRISPR-Cas9 screening identifies ATOX1 as a critical driver of cisplatin resistance. ATOX1 is highly expressed in liver cancer tissues, correlates with poor prognosis, and its knockdown enhances cisplatin sensitivity in vitro and in vivo. Molecular dynamics and virtual screening reveal compound 8 as a potent ATOX1 inhibitor that synergizes with cisplatin by promoting copper accumulation and NOTCH1/HES1 pathway suppression through increased DNA methylation at the NOTCH1 promoter.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/crispr-cas9-screening-identifies-atox1-driven-cisplatin-resistance-mechanisms-in-liver-cancer-and-evaluates-targeted-inhibitor-efficacy/351319/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/crispr-cas9-screening-identifies-atox1-driven-cisplatin-resistance-mechanisms-in-liver-cancer-and-evaluates-targeted-inhibitor-efficacy/351319.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in liver cancer?","Question",{"text":112,"@type":113},"Cisplatin treatment is often hindered by drug resistance in liver cancer, reducing clinical efficacy and contributing to poor survival outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ATOX1 identified as relevant to cisplatin resistance?",{"text":117,"@type":113},"Genome-wide CRISPR-Cas9 screening was used, and ATOX1 emerged as a critical gene associated with cisplatin resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed mechanism by which compound 8 enhances cisplatin sensitivity?",{"text":121,"@type":113},"Compound 8 inhibits ATOX1 activity, leading to intracellular copper accumulation, which increases DNA methylation at the NOTCH1 promoter and suppresses the NOTCH1/HES1 signaling pathway, thereby sensitizing liver cancer cells to cisplatin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351319,1790918786,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","communications biology Article  \nA Nature Portfolio journal  \n[https://doi.org/10.1038/s42003-026-09722-8](https://doi.org/10.1038/s42003-026-09722-8)  \nCRISPR-Cas9 screening identiﬁes ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efﬁcacy  \n Check for updates  \nChujiao Hu 1,2,6, Huading Tai3,6, Renguang Zhu1,6, Zhengyu Shu1, Guanghao Guo4, Dan Ma5 , Shi Zuo2,4 , Lei Tang1  & Zhirui Zeng 3   \nLiver cancer treatment with cisplatin is often hindered by drug resistance. This study aimed to identify key genes associated with cisplatin resistance in liver cancer and develop targeted inhibitors. Using genome-wide CRISPR-Cas9 screening, ATOX1 was identiﬁed as a critical gene for cisplatin resistance. ATOX1 was highly expressed in liver cancer tissues and associated with poor prognosis. Knockdown of ATOX1 in liver cancer cells enhanced cisplatin sensitivity in vitro and in vivo. Molecular dynamics simulation and virtual screening identiﬁed compound8asa potentATOX1inhibitorwith high afﬁnity (Kd = 12.5 μM) and exhibited synergistic effects with cisplatin on liver cancer cell growth. Mechanistically, compound 8 inhibits the activity of ATOX1, leading to intracellular copper accumulation. The elevated copper levels subsequently promote increased DNA methylation at the NOTCH1 promoter, resulting in suppression of the NOTCH1/HES1 signaling pathway and enhancing the sensitivity of liver cancer cells to cisplatin. In conclusion, ATOX1is crucial for cisplatin resistance in liver cancer and linked to poor prognosis. Targeting ATOX1 with compound 8 may be a novel therapeutic strategy for overcoming cisplatin resistance.  \nLiver cancer is the sixth most common malignancy worldwide and a leading cause of cancer-related death1. Statistics showed that there are approximately 840,000 new cases and 780,000 deaths from liver cancer globally each year, with Chinese patients accounting for about half of the total cases2. Despite recent progress in multiple treatment modalities, including surgical resection, local therapies, and systemic treatments, the 5-year survival rate of liver cancer patients remains below 20%3. This is primarily attributed to latestage diagnosis, high recurrence rates, and resistance to existing therapeutic approaches4. Therefore, exploring the mechanisms of drug resistance in liver cancer and developing novel therapeutic strategies have signiﬁcant clinical implications5.  \nCisplatin, a classic platinum-based antitumor agent, induces tumor cell apoptosis by forming cross-links with DNA, thereby inhibiting DNA replication and transcription6. It is widely used in the treatment of various  \nsolid tumors, including liver cancer. However, liver cancer cells often exhibit intrinsic or acquired resistance to cisplatin, severely limiting its clinical efﬁcacy7. Currently known mechanisms of cisplatin resistance mainly include decreased drug uptake, increased drug efﬂux, enhanced DNA damage repair, dysregulated apoptotic pathways, and epigenetic alterations8. Among these, metal metabolism-related drug transport systems play a crucial role in cisplatin resistance, though the speciﬁc mechanisms remain incompletely elucidated.  \nAntioxidant Protein 1 (ATOX1) is a copper chaperone protein whose primary function is to transfer intracellular copper ions from the copper transporter CTR1 to ATP7A/B, participating in the maintenance of intracellular copper homeostasis9, 10. ATOX1 binds copper ions through its conserved CXXC motif (including Cys12 and Cys15 residues), forming astable coordination structure11. Recent studies have discovered that ATOX1  \n1State Key Laboratory of Discovery and Utilization of Functional Components inTraditional Chinese Medicine, Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, Guizhou Medical University, Guiyang, China. 2Key Laboratory for Cancer Prevention and treatment of Guizhou Province, Guizhou Medical University, Guiyang, China. 3Tr","cbCaitAo30MXVUFW","https://ap.wps.com/l/cbCaitAo30MXVUFW","pdf",9200940,22,"English","# Background\n## Cisplatin resistance in liver cancer\n# Study approach\n## Genome-wide CRISPR-Cas9 screening\n# Key findings\n## ATOX1 as a resistance gene\n## Compound 8 as a targeted inhibitor\n# Mechanistic model\n## Copper accumulation and NOTCH1/HES1 suppression\n# Conclusion\n## Therapeutic implications for overcoming resistance","[{\"question\":\"What problem does the study address in liver cancer?\",\"answer\":\"Cisplatin treatment is often hindered by drug resistance in liver cancer, reducing clinical efficacy and contributing to poor survival outcomes.\"},{\"question\":\"How was ATOX1 identified as relevant to cisplatin resistance?\",\"answer\":\"Genome-wide CRISPR-Cas9 screening was used, and ATOX1 emerged as a critical gene associated with cisplatin resistance.\"},{\"question\":\"What is the proposed mechanism by which compound 8 enhances cisplatin sensitivity?\",\"answer\":\"Compound 8 inhibits ATOX1 activity, leading to intracellular copper accumulation, which increases DNA methylation at the NOTCH1 promoter and suppresses the NOTCH1/HES1 signaling pathway, thereby sensitizing liver cancer cells to cisplatin.\"}]","CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacy | PDF",1790093536,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3282dc0dd1cfe1222cf9b66ca68bfb5f.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf32c19ed3152eccfab365324a3f048d.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59e10388b51eaf346bbdc273d9af4955.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b05100de702267da7e6f4df484689310.webp",980,1301]